Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In our present study, we determined the genetic proxy efficacy of GLP-1R-based agonists in reducing BMI and ameliorating metabolic risk factors
In addition, the analysis of human prostate cancer and prostate control specimens confirmed the aberrant expression of miR-124-3p, miR-129-5p, and miR-378 in primary tumors
Any discussion of laboratory applications refers solely to research environments and scientific workflows
Chen, J., Zheng, S., Hu, Y., Mou, X
US$ 23.51
US$ 22.98
US$ 29.27
US$ 24.36
US$ 24.38
US$ 26.10
US$ 23.57
